# Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

> **NCT00005023** · PHASE1 · COMPLETED · sponsor: **University of Washington**

## Conditions studied

- Breast Cancer
- Lung Cancer
- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** HER-2/neu peptide vaccine
- **BIOLOGICAL:** sargramostim

## Key facts

- **NCT ID:** NCT00005023
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** 2001-01
- **Final completion:** 2001-01
- **Target enrollment:** — (—)
- **Last updated:** 2017-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005023, "Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00005023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*